Aranesp 30 mcg

EUR 282.00

In stock

- +

 

SHOP WITH CONFIDENCE

Standard Worldwide Mail Shipping
Standard Worldwide Mail Shipping
All your parcels are delivered in
DISCREET PACKAGING 100%

Standard Worldwide Mail Shipping

IMPORTANT: the use of the drug Aranesp 30 mcg is possible only after medical consultation with your doctor. The information provided on the NewPharmacy website is not a substitute for medical advice.

Information about the drug Aranesp 30 mcg: instructions, prices, analogues, generic and other related drugs.

Buy Aranesp 30 mcg from NewPharmacy online         

Contents

Aranesp 30 mcg uses

  • treatment of anemia associated with chronic renal failure in adults and children 11 years and older;
  • treatment of symptomatic anemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Aranesp 30 mcg dosage

Treatment with Aranesp should be carried out by doctors who have experience in prescribing for the above-mentioned indications.

Aranesp (SureClick) is supplied ready for use in pre-filled syringe pens (PZSHR). PZSHR is intended only for subcutaneous injections. Instructions for the use of the drug, its handling and the procedure for its destruction are given in the section Special instructions for use.

Treatment of anemia in patients with chronic renal failure.

Aranesp can be administered subcutaneously or intravenously. Subcutaneous administration is preferred for patients who do not receive hemodialysis to prevent peripheral vein puncture. The goal of therapy is to increase the hemoglobin content to a level exceeding 110 g / l. For each patient, an individual selection of the required hemoglobin above 110 g/l is required. Avoid increasing hemoglobin by more than 20 g / l in 4 weeks or hemoglobin above 140 g/l. Clinical studies have shown that the individual response of the patient may be different. However, at the initial stages, the following recommendations should be followed, both for adults and for children, with subsequent optimization of therapy depending on clinical indications.

Treatment with Aranesp includes two stages - the correction phase and the maintenance phase:

Correction phase.

The initial dose for subcutaneous or intravenous administration should be 0.45 mcg/kg of body weight with a single weekly administration. Alternatively, for patients who do not receive dialysis, subcutaneous administration of the drug at an initial dose of 0.75 mcg/kg of body weight is allowed every two weeks. If the increase in the concentration of hemoglobin is insufficient (less than 10 g / l for 4 weeks), the dose of the drug is increased by approximately 25%. Increasing the dose of the drug should not be carried out more often than once every four weeks.

If the hemoglobin concentration increases by more than 25 g / l in four weeks, the dose of Aranespa should be reduced by 25-50%, depending on the rate of increase in hemoglobin. If the hemoglobin content exceeds 140 g / l, therapy should be interrupted until the hemoglobin decreases below 130 g / l, and then resume the administration of the drug at a dose reduced by about 25% relative to the previous one. Hemoglobin should be measured weekly or biweekly until it stabilizes. Subsequently, hemoglobin can be evaluated periodically.

The maintenance phase.

During the maintenance phase, you can continue with a single weekly administration of Aranesp or switch to administration every two weeks. When transferring patients on dialysis from weekly injections to a once-every-two-week regimen, the initial dose should be twice the dose administered once a week. For patients who do not receive dialysis, after reaching the required hemoglobin concentration against the background of the drug administration every two weeks, its subcutaneous administration can be performed once a month using the initial dose twice the previous dose administered every two weeks.

Titration of the dose to maintain the required hemoglobin concentration should be performed as often as required.

For each patient, an individual selection of the required hemoglobin above 110 g/l is required. If optimization of the Aranespa dose is necessary to maintain the required hemoglobin, it is recommended to increase it by approximately 25%. If there is an increase in hemoglobin of more than 20 g/l for 4 weeks, the dose of the drug should be reduced by approximately 25%, depending on the rate of increase, If the hemoglobin content exceeds 140 g/l, therapy should be interrupted until the concentration decreases below 130 g/l, and then resume administration of the drug at a dose less than about 25% relative to the previous one.

After any change in the dose or mode of administration, the hemoglobin content should be monitored every 1 or 2 weeks. Dose changes during the maintenance phase should be performed no more than once every two weeks.

If the route of administration of the drug is changed, the same doses of the drug should be used and the hemoglobin concentration should be monitored once every 1-2 weeks in order to maintain the required hemoglobin level.

Patients who receive one, two or three weekly injections of rfEpo can be switched to a single weekly Aranespa administration or its administration once every two weeks. The initial weekly dose of Aranespa (mcg/week) is determined by dividing the total weekly dose of rfEpo (IU/week) by 200. The initial dose of Aranespa (mcg / two weeks) in the biweekly administration mode is determined by dividing the total cumulative dose of rfEpo administered over a two-week period by 200. Due to the known individual variability, individual patients may need to titrate the doses until the optimal therapeutic effect is obtained.

When replacing RCHEPO with Aranesp, the hemoglobin level should be measured at least once a week or every two weeks, and the method of administration of the drug should remain unchanged.

Treatment of symptomatic anemia in cancer patients.

Aranesp should be administered subcutaneously in patients with anemia (at a hemoglobin concentration of less than 110 g/l).)

The recommended starting dose is 500 mcg (6.75 mcg / kg) when administered once every three weeks. If the clinical response after nine weeks is inadequate (fatigue, hemoglobin content), further therapy may be ineffective.

Alternatively, once a week, the drug can be administered at a dose of 2.25 mcg/kg of body weight.

The use of Aranespa is discontinued approximately four weeks after the end of chemotherapy.

The hemoglobin content should not exceed 130 g/l.

After reaching the target hemoglobin, the dose of the drug should be reduced by 25-50% to maintain the hemoglobin at the appropriate level. If necessary, a further dose reduction is allowed to prevent an increase in the hemoglobin concentration of more than 130 g/l.

If the rate of increase in hemoglobin exceeds 20 g / l for 4 weeks, the dose of the drug should be reduced by 25-50%.

Aranesp synonyms and analogues

International name: Darbepoetin, Darbepoetin alpha, Epoetin, Erythropoietin, EPO, Haematopoietin, Haemopoietin, Eritropoietina, Eritropoyetina, Hemopoyetina.

Pharmacological Group: Erythropoiesis stimulators

Analogues and related drugs of the medicine Aranesp:

Aranesp available forms

Release form: solution for injection 30 mcg 0.3 ml 1 syringe

Manufacturer: Amgen

Also available different dosage forms of Aranesp for sale:

Where to buy Aranesp 30 mcg online with delivery?

At NewPharmacy, you can buy Aranesp 30 mcg with Worldwide Mail Shipping. All medicines are shipped from Russia. We ship to all over the world, we don't ship to Germany.

We ship any medicines only after full payment is made. Aranesp 30 mcg cost is indicated for 1 pack (unit).

Our online pharmacy sells only original, 100% authentic medicines (drugs).

Our pharmacy does not have accounts in such services as Amazon, Ebay, Reddit or others.

 


Someone from the Norway - just purchased the goods:
Mircera 100 mcg